Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for Oromandibular Dystonia
NCT07792798Phase 1Completed
- Sponsor
- Sana'a University
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of botulinum toxin type A in oromandibular dystonia (OMD) (2 arms), sponsored by Sana'a University. Primary endpoint: Change in Oromandibular Dystonia Symptoms at 24 weeks. Started Sep 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
oromandibular dystonia (OMD)
Beyond the preview
Go deeper on NCT07792798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792798.